Pacritinib在骨髓纤维化中缩脾效果不依赖JAK2V617F等位基因负荷
结果显示,在低等位基因负荷或JAK2V617F阴性患者中,pacritinib相比最佳可用治疗显著提高脾脏缓解率和症状改善率。
要点
- 低JAK2V617F负荷患者基线脾脏更小、血红蛋白和血小板更低。
- Pacritinib在所有等位基因负荷四分位及JAK2V617F阴性患者中均观察到脾脏缓解。
核心结论
- 在JAK2V617F阴性或低等位基因负荷的骨髓纤维化患者中,pacritinib相比最佳可用治疗可带来更优的脾脏和症状负担改善。
主要发现
- 低JAK2V617F负荷患者较高负荷患者基线脾脏更小、血红蛋白和血小板计数更低。
- Pacritinib组在所有JAK2V617F等位基因负荷四分位及JAK2V617F阴性患者中均观察到脾脏缓解。
- BAT组在等位基因负荷≤50%或JAK2V617F阴性患者中未观察到脾脏缓解。
临床怎么用
- 对于JAK2V617F阴性或低等位基因负荷的骨髓纤维化患者,pacritinib可能是一种独特的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) has heterogeneous clinical manifestations, with some patients exhibiting a myelodepletive phenotype characterized by cytopenias and an absent or low JAK2V617F allele burden. Ruxolitinib may be less effective in these patients. We assessed the efficacy of pacritinib, a JAK2/IRAK1 inhibitor, in MF patients with low JAK2V617F allele burden. In this post hoc analysis of the PERSIST-1 and -2 trials, patients with MF randomized to pacritinib or best available therapy (BAT) were stratified by JAK2V617F allele burden quartile for spleen response of ≥35% and improvement in total symptom score of ≥50%. Five hundred thirty-six patients were included. Patients with lower JAK2V617F allele burden had smaller baseline spleens and lower hemoglobin and platelet counts as compared with higher allele burden patients. Among pacritinib-treated patients, spleen responses were observed across all JAK2V617F allele burden quartiles and in JAK2V617F- disease. No spleen responses were observed among BAT-treated patients with allele burden ≤50% or JAK2V617F- disease. The intention-to-treat response rate was significantly higher on the pacritinib arm for JAK2V617F- disease (23.0% vs 0%; P = .033), and for the lowest allele burden quartiles (0%-25%: 20.9% vs 0%, P < .001; 25%-50%: 15.4% vs 0%, P = .020). There were significantly more symptom responders with pacritinib vs BAT in the 0% to 25% and 25% to 50% cohorts. Pacritinib treatment led to superior spleen and symptom burden reduction compared with BAT in patients with absent or low JAK2V617F allele burden, suggesting that pacritinib may be uniquely suited for patients with myelodepletive MF.
引用
- Tremblay D, Mesa R, Scott B, et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv. 2020. PMID: 33275766. doi:10.1182/bloodadvances.2020002970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。